Meeting
2023 ASCO Annual Meeting
Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.
Authors
David Hyams
Desert Surgical Oncology, Rancho Mirage, CA
David Hyams , Valentina I. Petkov , Jung S. Byun , Brian Martin , Christine N. Bailey , Brian Gastman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Real-World Data/Outcomes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6601)
DOI
10.1200/JCO.2023.41.16_suppl.6601
Abstract #
6601
Poster Bd #
93
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.
First Author: Georgina V. Long
Poster
2023 ASCO Annual Meeting
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
First Author: Kersti Oselin
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.
First Author: Revathi Kollipara